Key Financial Figures - Q2 FY27 Consolidated

  • Revenue: ₹192.3 crore, up 24.9% YoY from ₹153.9 crore
  • EBITDA: Growth of 38% YoY with margin expansion of approximately 290 basis points

Key Financial Figures - H1 FY27 Consolidated

  • Revenue: ₹372.5 crore, up 30.0% YoY from ₹286.5 crore
  • EBITDA: Growth of 58% YoY with margin expansion of approximately 530 basis points
  • Cash from Operations: ₹38 crores

Segmental Performance (H1 FY27)

  • Regulated Markets: ₹264.5 crore, up 34.3% YoY
  • Emerging Markets: ₹76.0 crore, up 25.3% YoY
  • Branded Generics: ₹17.5 crore, down 13.4% YoY
  • Others: ₹14.6 crore, up 67.2% YoY

Operational Highlights

  • ANDA Portfolio: Expanded from 34 ANDAs in September 2025 to 64 ANDAs in September 2026
  • Commercialized Products: 23 ANDAs have been commercialized
  • Pipeline: 41 ANDAs planned for launch over next 18-24 months
  • Manufacturing Facilities: 3 formulation facilities (USFDA approved Atlanta facility, USFDA approved Gujarat facility, WHO-GMP approved Chhatral facility) and 2 API facilities in India (Chhatral and Naroda)
  • Regulatory Approvals: Manufacturing facility in Chhatral approved by regulatory bodies of more than 10 countries for emerging markets
  • Product Registrations: 558 product registrations and 944 product applications for emerging markets

Impact on Profitability

The disclosure notes that EBITDA could have been higher but for initial set-up and operating costs associated with Zoraya and Amerisyn facilities, without corresponding revenue generation. These costs temporarily impacted profitability, with scale-up expected from FY28 onwards to drive operating leverage and improve margins.

Management Commentary

Mr. Swapnil Shah, Managing Director, commented on the company's 9th consecutive quarter of healthy double-digit growth. He highlighted strong execution, operational excellence, and diversified business operations as growth drivers. Specific mentions included:

  • Scaling up of Apnar facility
  • Upcoming contributions from Zoraya and Amerisyn
  • CDMO/CMO opportunities with pipeline of 41 molecules covering approximately 130 strengths
  • Entry into Europe and anticipated PIC/S approval for Chhatral facility
  • Investments in field-force expansion and market reach for critical care injectables business in India

Forward-looking Guidance

The company reaffirmed its FY27 outlook:

  • Revenue growth: 30-40%
  • PAT growth: 50-60%
  • Anticipated annual growth of 20-25% over the next two years (FY28-FY29)

This guidance is underpinned by robust product pipeline, expanded manufacturing capabilities, and strong commercial launch visibility.